|
Author | Country | Transplanted organ | Cohort size | Follow-up | Measure | Outcome |
|
Roth et al., 2011 [15] | USA | Kidney | | 10 years | Long-term outcome of RTx in HCV+ patients | RTx confers a long-term survival benefit |
|
Knoll et al., 1997 [16] | USA | Kidney | = 2053 HCV+ RTx Waiting list | 2 years | Outcomes in HCV+ RTx recipients to HCV+ ESRD patients | Decreased survival in HCV+ patients on waiting list compared to those who had RTx |
|
Fabrizi et al., 2005 [17] | Italy | Kidney | | | Outcome of RTx in HBV+ patients | Increased mortality in HBV+ recipients than HBV− recipients |
|
Reddy et al., 2011 [18] | USA | Kidney | = 75,861 HBV+ HBV− = 74,335 | 5 years | Patient/graft survival in HBV+ recipients | Patient/graft survival in HBV+ was comparable to HBV− recipients |
|
Sahi et al., 2007 [19] | USA | Lung | HCV+ | 3.2 years | Outcome of lung transplant in HCV+ recipients compared to HCV− controls | No significant difference in patient and graft survival |
|
Hartwig et al., 2005 [20] | USA | Lung | HB group HC group | | Outcome of the use of HbcAb+ and HCVAb+ allografts | Use of HbcAb+ allografts in recipients with prior immunisation was safe |
|
Dhillon et al., 2009 [21] | USA | Heart-lung | HbcAb+ HbcAb− = 13,233 | 5 years | Impact of donor HbcAb+ status on outcomes of lung and heart-lung recipients | Lungs and heart-lung allografts from HbcAb+ donors may be safely used |
|
Singal et al., 2013 [22] | USA | Liver | = 54687 | 5 years | Outcomes of liver transplant based on etiology of liver disease | Worst outcome in HCV+, HCV+, and alcohol |
|
Reddy and Everson 2013 [23] | USA | Liver | | 60 weeks | Treatment of HCV recurrence with protease inhibitor based therapy | Intervention with protease based therapy is justified in HCV eradication |
|